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An international interlaboratory proficiency testing program for the measurement of antifungal drugs was
initiated in 2007. This first round was limited to azole antifungals: fluconazole, itraconazole and hydroxyitra-
conazole, voriconazole, and posaconazole. The results demonstrate the need for and utility of an ongoing
proficiency testing program to further improve the analytical methods for routine patient management and
clinical research.
The measurement of plasma concentrations of azole anti-
fungals is often used in a research setting to assess the phar-
macokinetic behavior of these drugs and to characterize their
pharmacokinetic drug-drug interactions. In the clinical setting,
reports have emerged on the relationship between plasma con-
centrations and efficacy or toxicity for selected azoles, suggest-
ing the usefulness of therapeutic drug monitoring (TDM) of
azole antifungals, especially for itraconazole (ITZ) (3), vori-
conazole (VRZ) (6), and posaconazole (PSZ) (7). By means of
TDM, a clinician is able to individualize a drug dosage to
improve its efficacy and reduce toxicity by optimizing target
attainment. The TDM of azoles has now been included in the
updated guidelines for the treatment of invasive aspergillosis
by the Infectious Diseases Society of America (IDSA) (9).
The wide application of analytical methods for azole anti-
fungal drugs requires intralaboratory and interlaboratory qual-
ity control (QC) procedures to ensure that these methods have
sufficient accuracy, precision, and specificity. Participation in
interlaboratory proficiency testing programs is common prac-
tice for many infectious disease drugs (1, 4, 5, 8), but such a
program incorporating all currently marketed azole antifungal
drugs has not been available so far. Therefore, we initiated an
international interlaboratory proficiency testing program for
the measurement of azole antifungal agents.
Methods. Drug-free plasma from selected healthy volun-
teers was obtained through plasmapheresis with 100 ml of 4%
sodium citrate and was provided by the Dutch Blood Bank
(Sanquin, Nijmegen, The Netherlands). All antifungal azoles
were obtained from pharmaceutical companies and had a very
high (99%) specified purity. Purity was checked based on
analytical certificates provided by the supplier of the drug.
Samples were prepared using 3 ml of human plasma that was
spiked with fluconazole (FLZ), ITZ, hydroxyitraconazole
(hITZ), VRZ, and PSZ. The azole compounds were weighed
out on an independently calibrated balance, subsequently dis-
solved in methanol, and diluted with blank human plasma to
obtain five different samples. Sample 1 contained a combina-
tion of FLZ, ITZ, hITZ, and VRZ (Table 1). Samples 2 and 3
contained a low and high concentration, respectively, of VRZ.
Samples 4 and 5 contained a low and high concentration,
respectively, of PSZ. The QC samples were dispensed in
polypropylene vials and stored at 40°C until shipment. Sta-
bility at 40°C, 4°C, and ambient temperature (including the
daylight environment at ambient temperature) was proven for
at least 14 days, including three freeze-thaw cycles. All samples
were dispatched at ambient temperature.
All weighed-in concentrations were considered true values,
and the obtained concentrations were all within a concentra-
tion range that is generally achieved after the oral or intrave-
nous administration of azole drugs. The samples were analyzed
with our own validated high-performance liquid chromatogra-
phy (HPLC) method as a confirmative check (less than a 5%
deviation from the true concentration) before the samples
were released for the QC program.
Forty laboratories from four different continents (North
America, Europe, Asia, and Australia) whose scientists have
published on the bioanalysis of antifungal azoles were invited
to participate, free of charge, in the first round of the QC
program. The participants were requested to analyze the sam-
ples within 6 weeks after they were dispatched and were asked
to provide details about their analytical methods.
Descriptive statistics were calculated after the standardization
of all laboratory results to percentages with reference to the true
value. The deviation from the true concentration (inaccuracy) was
calculated by the subtraction of 100% from these percentages.
Concentrations within 20% of the weighed-in concentration
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were considered to be satisfactory or correct (2). A one-way
analysis of variance was performed to determine whether the
drug to be analyzed was of influence on the absolute inaccu-
racies of the laboratories. An unpaired t test was performed on
the absolute inaccuracies to determine a difference in the an-
alytical methods. A paired samples t test was performed on the
absolute inaccuracies, in order to determine if there was a
difference between performances for the high versus low con-
centrations of PSZ and VRZ. All statistical analyses were
performed using SPSS 14.0 (SPSS, Inc., Chicago, IL). A P
value of 0.05 was considered statistically significant. All par-
ticipants were provided feedback on their performance within
3 months after the first rounds’ deadline. The results from the
other laboratories were reported anonymously.
Results. Thirty-six laboratories subscribed to the program;
33 laboratories returned results that could be evaluated. The
laboratories used HPLC with either fluorescence, UV, or di-
ode-array detection (n  26), liquid chromatography-mass
spectrometry (LC-MS; n  6), or bioassay (n  3) techniques
to measure the azoles. Two laboratories used a combination of
techniques to measure different azole antifungal drugs. None
of the laboratories reported lower limits of quantitation that
were above the spiked concentrations, indicating the suitability
of these methods in clinical practice.
The percentages of correct analyses within the predefined
range of 80 to 120% of the weighed-in concentrations were as
follows: FLZ, 79% (n  14 analyses); ITZ, 78% (n  23);
hITZ, 78% (n  18); VRZ, 82% (n  57); and PSZ, 62% (n 
26) (Fig. 1). The mean absolute inaccuracy (and 95% confi-
dence interval) for each specific method was 20.74 (12.36 to
29.11) for HPLC, 17.70 (13.13 to 22.28) for LC-MS, and 6.33
(0.59 to 13.25) for bioassays. No difference in the absolute
inaccuracies was observed in the performance of HPLC with
UV or fluorescence detection versus LC-MS techniques (P 
0.615, unpaired t test). No comparison could be made with
regard to the bioassays since the numbers were too small to
make a valid statement. All of the participating laboratories
using a bioassay reported adequate values within the 80 to
TABLE 1. Concentrations (in mg/liter) of the azole antifungals in
the QC samples
Sample FLZ ITZ hITZ VRZ PSZ
1 8.17 0.55 1.01 2.11
2 0.51
3 2.03
4 3.00
5 0.30
FIG. 1. Deviation from the declared value. The horizontal solid lines represent the median value. The filled symbols indicate HPLC results, the
unfilled symbols indicate LC-MS results, and the unfilled symbols with crosses indicate bioassay results. Four data points are outside the axis limits
and are not shown in the graph: one laboratory reported ITZ at 17,595%, another laboratory reported hITZ at 126%, and a third laboratory
reported 0.30 mg/liter posaconazole at 300% and 3.00 mg/liter posaconazole at 231%.
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120% range. Laboratories using the bioassay were not able to
measure the concentrations of azole antifungals in the com-
bined sample. A one-way analysis of variance yielded no sta-
tistically significant differences between the absolute inaccura-
cies related to the different azole antifungal drugs [F(4,86) 
0.884; P  0.477]. All results were correctly reported by 18 of
33 laboratories (54.5%).
The performance for the lowest concentration of PSZ was
less accurate than for the higher concentration (54% versus
69% correct analyses), but the test did not yield a statistical
significance (n  13; P  0.130, paired t test). For VRZ, there
was no difference between the high and low concentrations.
Laboratories were informed about their performance to enable
them to improve their methods.
Discussion. The purpose of our proficiency testing program
for the TDM of azole antifungals is to alert laboratories of
potential problems and is therefore a useful instrument to
monitor the accuracy of analytical methods.
The first results of this new QC program of azole antifungal
agents show a performance ranging between 62 and 82% and
thus clearly indicate the need to further improve analytical
methods. The data suggest that in particular, analysis of PSZ,
although not statistically significant from the other azoles, re-
quires attention. Inaccurate results may introduce bias in phar-
macokinetic studies or may provide a basis for incorrect dose
adjustments in TDM.
For a first round, the number of participating labs is rela-
tively high. However, even with this great contribution from all
participants, there are some minor drawbacks. Very low and
high concentrations outside the therapeutic range have not yet
been included so we were not able to elude problems with
lower limits of quantitation. Dispatching a combined sample of
azoles may provide efficiency in determining difficulties with
specificity and/or selectivity; however, this precludes laborato-
ries using bioassays from participation. Sources of error in the
current program have not been established. Therefore, no con-
clusions from this round on the reasons of inadequate perfor-
mance can be drawn. Future rounds will address potential
explanations for these shortcomings in more detail. These fu-
ture rounds are needed to establish whether the program in-
deed contributes to the improvement of antifungal azole anal-
ysis. The program will also be extended to more laboratories
and more antifungal drugs.
We express gratitude to our analytical staff (Corrien Verweij-van
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Eerland) for the preparation of the QC samples.
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